UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FOXO1‐RICTOR AXIS INDUCES AKT PHOSPHORYLATION DURING CLL CELL ADAPTATION TO BCR INHIBITORS: IMPLICATIONS FOR COMBINATORIAL THERAPY

Hematological oncology, 2023-06, Vol.41 (S2), p.54-56

2023

Volltextzugriff (PDF)

Abrogation of RUNX1 gene expression in de novo myelodysplastic syndrome with t(4;21)(q21;q22)

Haematologica (Roma), 2012-04, Vol.97 (4), p.534-537

2012

Volltextzugriff (PDF)

Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML 1 and Sp1 binding motifs

Leukemia, 2012, Vol.26 (6), p.1329-1337

2012

Volltextzugriff (PDF)

“Long COVID‐19” of Researchers: What to Do Next?

HemaSphere, 2022-01, Vol.6 (1), p.e673-n/a

2022

Volltextzugriff (PDF)

Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia

Cell reports (Cambridge), 2018-03, Vol.22 (13), p.3641-3659

2018

Volltextzugriff (PDF)

Effect of the COVID‐19 Pandemic on Laboratory and Clinical Research: A Testimony and a Call to Action From Researchers

HemaSphere, 2020-12, Vol.4 (6), p.e499-n/a

2020

Volltextzugriff (PDF)

Robust CRISPR‐Cas9 Genetic Editing of Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

HemaSphere, 2023-06, Vol.7 (6), p.e909-n/a

2023

Volltextzugriff (PDF)

MAPK8‐mediated stabilization of SP1 is essential for RUNX1‐RUNX1T1 – driven leukaemia

British journal of haematology, 2016-03, Vol.172 (5), p.807-810

2016

Volltextzugriff (PDF)

Biological, prognostic, and therapeutic impact of the epigenome in CLL

Seminars in hematology, 2024-06, Vol.61 (3), p.172-180

2024

Volltextzugriff (PDF)

CRISPR-Cas9 Genome Editing of Primary Chronic Lymphocytic Leukemia Cells

Blood, 2022-11, Vol.140 (Supplement 1), p.9849-9850

2022

Volltextzugriff (PDF)

IRF2 Regulates De Novo Active Chromatin Regions and Participates in the Development and Pathogenesis of Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.1928-1928

2023

Volltextzugriff (PDF)

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies

Cancer cell, 2023-12, Vol.41 (12), p.2136-2153.e13

2023

Volltextzugriff (PDF)

Development of a Novel Chromatin Activation Score As a Powerful Independent Prognostic Factor in Chronic Lymphocytic Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.4123-4124

2022

Volltextzugriff (PDF)

Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.8774-8775

2022

Volltextzugriff (PDF)

HDAC Inhibitors As Novel Targeted Therapies for NUP98-HOXA9 AML Patients

Blood, 2016-12, Vol.128 (22), p.2685-2685

2016

Volltextzugriff (PDF)

Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1

Bioorganic & medicinal chemistry letters, 2017-07, Vol.27 (14), p.3190-3195

2017

Volltextzugriff (PDF)

Chromatin Modifications Induced by the AML1/ETO Fusion Protein Reversibly Silence Its Genomic Targets Through AML1 and Sp1 Binding Motifs

Blood, 2011-11, Vol.118 (21), p.2422-2422

2011

Volltextzugriff (PDF)

Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal

Blood, 2014-03, Vol.123 (11), p.1729-1738

2014

Volltextzugriff (PDF)

Abstract PO-023: CD70 deregulation in follicular lymphoma at diagnosis is associated with relapse and opens new avenues for dual CD19-CD70 CAR-T therapy

Blood cancer discovery, 2024-06, Vol.5 (3_Supplement), p.PO-023-PO-023

2024

Volltextzugriff (PDF)

MAPK 8‐mediated stabilization of SP 1 is essential for RUNX 1‐ RUNX 1T1 – driven leukaemia

British journal of haematology, 2016-03, Vol.172 (5), p.807-810

2016

Volltextzugriff (PDF)

Abstract 472: Interactions of the fusion protein Nup98-Hoxa9 with Pbx3, p300 and HDAC1: widening the targeted therapy window in acute myeloid leukemia (AML)

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.472-472

2014

Volltextzugriff (PDF)

Inhibit a kinase to degrade a histone demethylase: a candidate therapeutic approach in glioblastoma

Translational cancer research, 2017-02, Vol.6 (S1), p.S57-S60

2017

Volltextzugriff (PDF)

Pharmacological Inhibitors of LSD1 Promote Differentiation of Myeloid Leukemia Cells through a Mechanism Independent of Histone Demethylation

Blood, 2014-12, Vol.124 (21), p.267-267

2014

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

ThemaLeukemia

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

FOXO1‐RICTOR AXIS INDUCES AKT PHOSPHORYLATION DURING CLL CELL ADAPTATION TO BCR INHIBITORS: IMPLICATIONS FOR COMBINATORIAL THERAPY

Abrogation of RUNX1 gene expression in de novo myelodysplastic syndrome with t(4;21)(q21;q22)

Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML 1 and Sp1 binding motifs

“Long COVID‐19” of Researchers: What to Do Next?

Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia

Effect of the COVID‐19 Pandemic on Laboratory and Clinical Research: A Testimony and a Call to Action From Researchers

Robust CRISPR‐Cas9 Genetic Editing of Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

S142: FOXO1‐RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY

MAPK8‐mediated stabilization of SP1 is essential for RUNX1‐RUNX1T1 – driven leukaemia

Biological, prognostic, and therapeutic impact of the epigenome in CLL

CRISPR-Cas9 Genome Editing of Primary Chronic Lymphocytic Leukemia Cells

IRF2 Regulates De Novo Active Chromatin Regions and Participates in the Development and Pathogenesis of Multiple Myeloma

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies

Development of a Novel Chromatin Activation Score As a Powerful Independent Prognostic Factor in Chronic Lymphocytic Leukemia

Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia

HDAC Inhibitors As Novel Targeted Therapies for NUP98-HOXA9 AML Patients

Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1

Chromatin Modifications Induced by the AML1/ETO Fusion Protein Reversibly Silence Its Genomic Targets Through AML1 and Sp1 Binding Motifs

Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal

Abstract PO-023: CD70 deregulation in follicular lymphoma at diagnosis is associated with relapse and opens new avenues for dual CD19-CD70 CAR-T therapy

MAPK 8‐mediated stabilization of SP 1 is essential for RUNX 1‐ RUNX 1T1 – driven leukaemia

FoxO1/Rictor axis induces a non-genetic adaptation to Ibrutinib via Akt activation in chronic lymphocytic leukemia

Abstract 472: Interactions of the fusion protein Nup98-Hoxa9 with Pbx3, p300 and HDAC1: widening the targeted therapy window in acute myeloid leukemia (AML)

Inhibit a kinase to degrade a histone demethylase: a candidate therapeutic approach in glioblastoma

Pharmacological Inhibitors of LSD1 Promote Differentiation of Myeloid Leukemia Cells through a Mechanism Independent of Histone Demethylation

Aktive Filter

Suchergebnisse filtern